Bucelipase alfa

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBucelipase alfa
Drug Alias NamerhBSSL布塞脂酶αbucelipasa alfaBile salt-stimulated lipaserecombinant human BSSL +[12] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionLipase replacements
TargetsCholesterol esterTriglyceride
Therapy Area/IndicationsExocrine Pancreatic InsufficiencyCystic FibrosisMalabsorption Syndromes
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryPolandNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSobiSwedish Orphan Biovitrum (Sobi)Astrazeneca Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsExocrine Pancreatic InsufficiencyCystic FibrosisMalabsorption Syndromes

Other Information

ATC CodeN/A
Related LinksN/A